Cure My Disease

Don't miss your cure!

 Log in / Sign up

Cancer patients get second chance with modified cell therapy

NCT ID NCT04094311

Recruiting now Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

Summary

This study tests a modified version of a cell therapy (tisagenlecleucel) for patients with aggressive blood cancers when their manufactured treatment doesn't meet standard release specifications. It involves 200 children and adults with relapsed leukemia or lymphoma who have no other appropriate treatment options. The research evaluates whether this modified therapy is safe and effective for patients with serious, life-threatening conditions.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-••••

Locations

  • Novartis Investigative Site

    COMPLETED

    Hamilton, Ontario, L8V 5C2, Canada

  • Novartis Investigative Site

    WITHDRAWN

    Ottawa, Ontario, K1H 8L6, Canada

  • Novartis Investigative Site

    COMPLETED

    Toronto, Ontario, M5G 1X8, Canada

  • Novartis Investigative Site

    COMPLETED

    Toronto, Ontario, M5G 2M9, Canada

  • Novartis Investigative Site

    WITHDRAWN

    Montreal, Quebec, H1T 2M4, Canada

  • Novartis Investigative Site

    WITHDRAWN

    Québec, Quebec, G1R 2J6, Canada

  • Novartis Investigative Site

    RECRUITING

    Nagoya, Aichi-ken, 4668560, Japan

  • Novartis Investigative Site

    RECRUITING

    Nagoya, Aichi-ken, 4678602, Japan

  • Novartis Investigative Site

    RECRUITING

    Tōon, Ehime, 7910295, Japan

  • Novartis Investigative Site

    RECRUITING

    Gifu, Gifu, 501-1194, Japan

  • Novartis Investigative Site

    RECRUITING

    Sapporo, Hokkaido, 0608543, Japan

  • Novartis Investigative Site

    RECRUITING

    Sapporo, Hokkaido, 0608648, Japan

  • Novartis Investigative Site

    RECRUITING

    Kobe, Hyōgo, 6500047, Japan

  • Novartis Investigative Site

    RECRUITING

    Nishinomiya, Hyōgo, 663 8501, Japan

  • Novartis Investigative Site

    RECRUITING

    Tsukuba, Ibaraki, 3058576, Japan

  • Novartis Investigative Site

    RECRUITING

    Kanazawa, Ishikawa-ken, 920 8641, Japan

  • Novartis Investigative Site

    RECRUITING

    Kita-gun, Kagawa-ken, 7610793, Japan

  • Novartis Investigative Site

    RECRUITING

    Yokohama, Kanagawa-ku, 236-0004, Japan

  • Novartis Investigative Site

    RECRUITING

    Kyoto, Kyoto, 602-8566, Japan

  • Novartis Investigative Site

    RECRUITING

    Tsu, Mie-ken, 514-8507, Japan

  • Novartis Investigative Site

    RECRUITING

    Sendai, Miyagi, 9808574, Japan

  • Novartis Investigative Site

    RECRUITING

    Matsumoto, Nagano, 3908621, Japan

  • Novartis Investigative Site

    RECRUITING

    Nagasaki, Nagasaki, 852-8501, Japan

  • Novartis Investigative Site

    RECRUITING

    Yufu, Oita Prefecture, 8795593, Japan

  • Novartis Investigative Site

    RECRUITING

    Kurashiki, Okayama-ken, 7108602, Japan

  • Novartis Investigative Site

    RECRUITING

    Izumi, Osaka, 5941101, Japan

  • Novartis Investigative Site

    RECRUITING

    Izumisano, Osaka, 5988577, Japan

  • Novartis Investigative Site

    RECRUITING

    Osaka, Osaka, 5418567, Japan

  • Novartis Investigative Site

    RECRUITING

    Sakai, Osaka, 590-0197, Japan

  • Novartis Investigative Site

    RECRUITING

    Suita, Osaka, 5650871, Japan

  • Novartis Investigative Site

    RECRUITING

    Izumo, Shimane, 693 8501, Japan

  • Novartis Investigative Site

    RECRUITING

    Hamamatsu, Shizuoka, 4313192, Japan

  • Novartis Investigative Site

    RECRUITING

    Bunkyo Ku, Tokyo, 1138431, Japan

  • Novartis Investigative Site

    RECRUITING

    Bunkyo Ku, Tokyo, 1138655, Japan

  • Novartis Investigative Site

    RECRUITING

    Bunkyo Ku, Tokyo, 1138677, Japan

  • Novartis Investigative Site

    RECRUITING

    Bunkyo-ku, Tokyo, 1138519, Japan

  • Novartis Investigative Site

    RECRUITING

    Chuo Ku, Tokyo, 1040045, Japan

  • Novartis Investigative Site

    RECRUITING

    Fuchū, Tokyo, 1838524, Japan

  • Novartis Investigative Site

    RECRUITING

    Minato-ku, Tokyo, 105-8471, Japan

  • Novartis Investigative Site

    RECRUITING

    Setagaya-ku, Tokyo, 1578535, Japan

  • Novartis Investigative Site

    RECRUITING

    Shinjuku-ku, Tokyo, 1608582, Japan

  • Novartis Investigative Site

    RECRUITING

    Aomori, 030 8553, Japan

  • Novartis Investigative Site

    RECRUITING

    Chiba, 260 8677, Japan

  • Novartis Investigative Site

    RECRUITING

    Fukuoka, 8128582, Japan

  • Novartis Investigative Site

    RECRUITING

    Hiroshima, 7348551, Japan

  • Novartis Investigative Site

    RECRUITING

    Kumamoto, 860-8556, Japan

  • Novartis Investigative Site

    RECRUITING

    Kyoto, 6068507, Japan

  • Novartis Investigative Site

    RECRUITING

    Niigata, 9518520, Japan

  • Novartis Investigative Site

    RECRUITING

    Okayama, 7008558, Japan

  • Novartis Investigative Site

    RECRUITING

    Osaka, 543-8555, Japan

  • Novartis Investigative Site

    RECRUITING

    Osaka, 5458586, Japan

  • Novartis Investigative Site

    RECRUITING

    Saitama, 3308777, Japan

  • Novartis Investigative Site

    RECRUITING

    Wakayama, 641-8510, Japan

Conditions

Explore the condition pages connected to this study.

B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA DIFFUSE LARGE B CELL LYMPHOMA